GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Upper GI Tract/Exclusive Enteral Nutrition Shows Modest but Meaningful Benefit in Adult Crohn’s Disease | Indian Journal of Gastroenterology

Exclusive Enteral Nutrition Shows Modest but Meaningful Benefit in Adult Crohn’s Disease | Indian Journal of Gastroenterology

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated May 1, 2026

Quick Answer

Introduction Exclusive enteral nutrition (EEN) is a well-established induction therapy in pediatric Crohn’s disease, where it offers anti-inflammatory efficacy while avoiding corticosteroid-related toxicity. In adults, however, EEN has been less widely adopted because of concerns regarding adherence, palatability and uncertain comparative effectiveness relative to standard medical therapy.


Introduction

Exclusive enteral nutrition (EEN) is a well-established induction therapy in pediatric Crohn’s disease, where it offers anti-inflammatory efficacy while avoiding corticosteroid-related toxicity. In adults, however, EEN has been less widely adopted because of concerns regarding adherence, palatability and uncertain comparative effectiveness relative to standard medical therapy.

Problem Statement

The role of EEN in adult Crohn’s disease remains poorly defined due to heterogeneous study designs, variable nutritional formulations and inconsistent remission outcomes across clinical trials. Whether EEN can serve as a practical steroid-sparing strategy in adults—and in which clinical settings it may be most useful—has remained an important unresolved question in inflammatory bowel disease management.

Summary

This systematic review and meta-analysis demonstrates that EEN can induce clinical remission in adults with active Crohn’s disease, although its efficacy appears inferior to corticosteroids for remission induction. Across real-world studies, approximately two-thirds of patients achieved remission with EEN, supporting its meaningful anti-inflammatory potential in selected adult populations. Importantly, the analysis found no significant difference in efficacy between elemental and non-elemental formulations, suggesting that therapeutic benefit is independent of formula composition and allowing greater flexibility in nutritional strategy. The review also highlights emerging evidence supporting combination therapy, where EEN used alongside biologics may improve remission outcomes compared with biologic therapy alone. Adverse events were generally mild, with poor palatability remaining the principal limitation affecting tolerability and adherence. These findings reinforce that while EEN is unlikely to replace corticosteroids as first-line induction therapy in most adults, it remains an important steroid-sparing and nutritionally supportive option, particularly in patients where corticosteroid avoidance is desirable or adjunctive nutritional therapy is clinically beneficial. The study supports a more individualized role for EEN within modern adult Crohn’s disease management.

Related Q&A

Basal Crypt Dysplasia in Barrett's Esophagus: GUT | July 2026

Introduction: Barrett's esophagus (BE) is the principal precursor of esophageal adenocarcinoma. Early detection of neoplastic transformation is essential for preventing cancer progression. This review discusses basal crypt dysplasia (CD), an emerging histological entity that may...

High-Resolution Impedance Manometry after POEM: AJG | May 2026

Introduction: Assessing esophageal clearance after peroral endoscopic myotomy (POEM) is essential for evaluating treatment success in achalasia. Timed barium esophagram (TBE) is the current standard, but high-resolution impedance manometry (HRiM) may provide a radiation-free physiological...

Magnetic Sphincter Augmentation Provides Durable GERD Control : Ann Surg | Jun 2026

Introduction: Magnetic sphincter augmentation (MSA) has emerged as an effective surgical option for patients with gastroesophageal reflux disease (GERD) who continue to experience symptoms despite medical therapy. By augmenting lower esophageal sphincter function while preserving...

New Strategies Needed for Resistant H. pylori : Indian J Gastroenterol | Jun 2026

Introduction: Helicobacter pylori infection affects more than half of the global population and remains a major cause of peptic ulcer disease, gastric mucosal inflammation, and gastric cancer. Successful eradication is a cornerstone of gastrointestinal practice,...

Vonoprazan–Tetracycline Dual Therapy Simplifies H. pylori Rescue Treatment : Gastroenterology | June 2026

Introduction: Helicobacter pylori Infection eradication after prior treatment failure remains a major therapeutic challenge due to increasing antibiotic resistance, poor tolerability of multidrug regimens and declining adherence rates. Simplified rescue strategies with improved safety and...

H. pylori Eradication Reduces Cancer but Mortality Benefit Remains Fragile : Gastroenterology | June 2026

Introduction Helicobacter pylori Infection eradication is widely accepted as a key strategy for prevention of Gastric Cancer. Large meta-analyses have consistently shown reductions in gastric cancer incidence following eradication therapy, supporting global screening and treatment...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer